Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swathi Ramakrishnan

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinomaSwathi Ramakrishnan, Roberto Pili
Epigenomics|July 31, 2013
Histone modifications: implications in renal cell carcinomaSwathi Ramakrishnan, Leigh Ellis, Roberto Pili
The Prostate|July 29, 2011
Development of a castrate resistant transplant tumor model of prostate cancerLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Plos One|July 30, 2014
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerShengYu Ku, Elena Lasorsa, Remi Adelaiye, et al.
Metabolites|February 25, 2023
Serum Androgen Metabolites Correlate with Clinical Variables in African and European American Men with Localized, Therapy Naïve Prostate CancerSwathi Ramakrishnan, Rick A Kittles, Wendy J Huss, et al.
Oncotarget|October 29, 2013
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancerLeigh Ellis, Sheng Yu Ku, Swathi Ramakrishnan, et al.
American Journal of Clinical and Experimental Urology|July 25, 2018
Transcriptional changes associated with <i>in vivo</i> growth of muscle-invasive bladder cancer cell lines in nude miceSwathi Ramakrishnan, Wendy Huss, Barbara Foster, et al.
Plos One|February 4, 2012
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer modelsLi Shen, Michael Ciesielski, Swathi Ramakrishnan, et al.
Molecular Cancer Therapeutics|November 9, 2014
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma modelsEric Ciamporcero, Kiersten Marie Miles, Remi Adelaiye, et al.
Plos One|November 17, 2011
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinomaSwathi Ramakrishnan, Roberto Pili
Epigenomics|July 31, 2013
Histone modifications: implications in renal cell carcinomaSwathi Ramakrishnan, Leigh Ellis, Roberto Pili
The Prostate|July 29, 2011
Development of a castrate resistant transplant tumor model of prostate cancerLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Plos One|July 30, 2014
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerShengYu Ku, Elena Lasorsa, Remi Adelaiye, et al.
Metabolites|February 25, 2023
Serum Androgen Metabolites Correlate with Clinical Variables in African and European American Men with Localized, Therapy Naïve Prostate CancerSwathi Ramakrishnan, Rick A Kittles, Wendy J Huss, et al.
Oncotarget|October 29, 2013
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancerLeigh Ellis, Sheng Yu Ku, Swathi Ramakrishnan, et al.
American Journal of Clinical and Experimental Urology|July 25, 2018
Transcriptional changes associated with <i>in vivo</i> growth of muscle-invasive bladder cancer cell lines in nude miceSwathi Ramakrishnan, Wendy Huss, Barbara Foster, et al.
Plos One|February 4, 2012
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer modelsLi Shen, Michael Ciesielski, Swathi Ramakrishnan, et al.
Molecular Cancer Therapeutics|November 9, 2014
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma modelsEric Ciamporcero, Kiersten Marie Miles, Remi Adelaiye, et al.
Plos One|November 17, 2011
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Pageof 3